Marker Therapeutics Reports 78% Response Rate in MT-601 Trial Amid $16.1M Funding Boost
By ATTN Desk · Editorial oversight: Sean Han
Introduction to Marker Therapeutics, Inc.
Marker Therapeutics, Inc. (ticker: MRKR) is a clinical-stage immuno-oncology company headquartered in Houston, Texas. The company’s core technology, Multi-Antigen Recognizing (MAR) T cells, utilizes non-engineered T cells to target multiple tumor‐associated antigens simultaneously. Marker’s lead product candidate, MT-601, recognizes six tumor-specific antigens (Survivin, PRAME, NY-ESO-1, MAGE-A4, SSX2, WT-1) and is being evaluated in the Phase 1 APOLLO study for patients with lymphoma who have relapsed after or are ineligible for anti-CD19 CAR-T therapy.
Corporate Structure and Team
Marker Therapeutics employs a team of scientists, clinicians, and manufacturing specialists with experience in cancer immunotherapy. The MAR-T platform originated at Baylor College of Medicine, and the company’s Houston-based team focuses on translational research, clinical development, and cGMP manufacturing. While specific headcount figures are not publicly disclosed, Marker emphasizes a collaborative culture aimed at improving treatment options for cancer patients.
Immuno-oncology by National Cancer Institute
Recent Developments and News
• In May 2025, Marker Therapeutics completed a $16.1 million private placement to support further enrollment and data collection in its Phase 1 APOLLO study.
• In May 2025, the company reported that among nine evaluable patients in the APOLLO trial, MT-601 achieved a 78% objective response rate, including a 44.4% complete response rate. No dose-limiting toxicities or cases of ICANS were observed.
• On May 28, 2025, President and CEO Juan Vera participated in a virtual salon titled “CAR-T Therapies: After Seven Years, The Results Are In, And The Debate Isn’t Over,” alongside experts from Baylor College of Medicine and the University of Colorado.
• In June 2025, Marker Therapeutics entered into a collaboration with Cellipont Bioservices to advance cGMP manufacturing of MT-601, with the goal of enhancing clinical supply and preparing for potential pivotal studies.
Financial and Strategic Aspects
Marker Therapeutics filed Form 8-K reports on May 20, June 9, and June 17, 2025, disclosing significant corporate events under Items 1.01, 5.07, 8.01, and 9.01. These filings indicate operational updates but do not include detailed financial statements. Stakeholders seeking comprehensive revenue, profitability, and cash flow data should refer to the company’s 10-Q and 10-K filings.
As of July 17, 2025, MRKR trades on NASDAQ at $2.4891 per share, reflecting a 55.57% increase in the latest session on a volume of 2,754,960 shares:
| Ticker | Exchange | Price (USD) | Change (%) | Volume |
|---|---|---|---|---|
| MRKR | NASDAQ | 2.4891 | +55.57 | 2,754,960 |
Strategically, Marker’s MAR-T approach may provide benefits over gene-modified CAR-T and TCR therapies, including simpler manufacturing processes and a favorable safety profile, while effectively addressing tumor heterogeneity through multi-antigen targeting.
Market Position and Industry Context
The cell therapy landscape includes genetically engineered CAR-T and TCR products that are approved for hematologic malignancies, with ongoing developments aimed at solid tumors. Marker’s non-engineered MAR-T cells differentiate themselves by utilizing natural T-cell receptors to recognize multiple antigens. This platform could potentially reduce risks associated with gene editing and minimize production complexities. As the company continues to advance MT-601 through clinical trials and scale its manufacturing capabilities, it aims to position itself as an alternative immunotherapy option in a competitive market.
tl;dr
Marker Therapeutics’ MT-601 is currently in a Phase 1 APOLLO trial for CAR-T relapsed or ineligible lymphoma patients. In May 2025, the company secured $16.1 million in private financing and reported a 78% response rate (44.4% complete responses) among nine evaluable patients. In June 2025, Marker partnered with Cellipont Bioservices to enhance cGMP manufacturing, preparing for potential pivotal studies.